RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Regeneron Pharmaceuticals Stock

Regeneron Pharmaceuticals Net Income 2024

Regeneron Pharmaceuticals Net Income

5.07 B USD

Ticker

REGN

ISIN

US75886F1075

WKN

881535

In 2024, Regeneron Pharmaceuticals's profit amounted to 5.07 B USD, a 28.13% increase from the 3.95 B USD profit recorded in the previous year.

The Regeneron Pharmaceuticals Net Income history

YEARNET INCOME (undefined USD)
2029e8.14
2028e7.38
2027e6.78
2026e6.17
2025e5.5
2024e5.07
20233.95
20224.34
20218.08
20203.51
20192.12
20182.44
20171.2
20160.9
20150.64
20140.34
20130.42
20120.75
2011-0.22
2010-0.1
2009-0.07
2008-0.08
2007-0.11
2006-0.1
2005-0.1
20040.04

Regeneron Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Regeneron Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Regeneron Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Regeneron Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Regeneron Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Regeneron Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Regeneron Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Regeneron Pharmaceuticals’s growth potential.

Regeneron Pharmaceuticals Revenue, EBIT and net profit per share

DateRegeneron Pharmaceuticals RevenueRegeneron Pharmaceuticals EBITRegeneron Pharmaceuticals Net Income
2029e20.08 B undefined0 undefined8.14 B undefined
2028e18.94 B undefined7.89 B undefined7.38 B undefined
2027e17.88 B undefined7.19 B undefined6.78 B undefined
2026e16.7 B undefined6.66 B undefined6.17 B undefined
2025e15.69 B undefined5.94 B undefined5.5 B undefined
2024e14.45 B undefined5.31 B undefined5.07 B undefined
202313.12 B undefined4.34 B undefined3.95 B undefined
202212.17 B undefined4.99 B undefined4.34 B undefined
202116.07 B undefined8.95 B undefined8.08 B undefined
20208.5 B undefined3.58 B undefined3.51 B undefined
20197.86 B undefined2.21 B undefined2.12 B undefined
20186.71 B undefined2.53 B undefined2.44 B undefined
20175.87 B undefined2.08 B undefined1.2 B undefined
20164.86 B undefined1.33 B undefined896 M undefined
20154.1 B undefined1.25 B undefined636 M undefined
20142.82 B undefined823 M undefined338 M undefined
20132.11 B undefined760 M undefined424 M undefined
20121.38 B undefined458 M undefined750 M undefined
2011446 M undefined-205 M undefined-222 M undefined
2010459 M undefined-97 M undefined-104 M undefined
2009379 M undefined-74 M undefined-68 M undefined
2008238 M undefined-87 M undefined-79 M undefined
2007125 M undefined-115 M undefined-107 M undefined
200663 M undefined-108 M undefined-102 M undefined
200566 M undefined-124 M undefined-95 M undefined
2004174 M undefined6 M undefined42 M undefined

Regeneron Pharmaceuticals stock margins

The Regeneron Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Regeneron Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Regeneron Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Regeneron Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Regeneron Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Regeneron Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Regeneron Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Regeneron Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Regeneron Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Regeneron Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Regeneron Pharmaceuticals Margin History

Regeneron Pharmaceuticals Gross marginRegeneron Pharmaceuticals Profit marginRegeneron Pharmaceuticals EBIT marginRegeneron Pharmaceuticals Profit margin
2029e86.94 %0 %40.54 %
2028e86.94 %41.62 %38.98 %
2027e86.94 %40.24 %37.91 %
2026e86.94 %39.87 %36.94 %
2025e86.94 %37.82 %35.07 %
2024e86.94 %36.77 %35.06 %
202386.94 %33.05 %30.14 %
202287.18 %41.03 %35.64 %
202184.83 %55.67 %50.24 %
202086.82 %42.1 %41.34 %
201990.05 %28.11 %26.91 %
201893.53 %37.76 %36.42 %
201793.24 %35.42 %20.42 %
201693.85 %27.39 %18.44 %
201590.42 %30.51 %15.5 %
201492.73 %29.18 %11.99 %
201392.59 %36.1 %20.14 %
201293.9 %33.24 %54.43 %
201199.1 %-45.96 %-49.78 %
201099.56 %-21.13 %-22.66 %
200999.74 %-19.53 %-17.94 %
2008100 %-36.55 %-33.19 %
2007100 %-92 %-85.6 %
200687.3 %-171.43 %-161.9 %
200586.36 %-187.88 %-143.94 %
200491.38 %3.45 %24.14 %

Regeneron Pharmaceuticals Aktienanalyse

What does Regeneron Pharmaceuticals do?

Regeneron Pharmaceuticals Inc. is an American biotechnology company founded in 1988 by Leonard Schleifer. The company is headquartered in Tarrytown, New York and employs approximately 8,500 people worldwide. Regeneron is known for its research in the areas of cancer therapies, eye diseases, and asthma. Regeneron operates a business model based on the research and development of biotechnological drugs. The company invests heavily in research and seeks new compounds that can fight inflammation and cancer. Regeneron develops its products using the reverse transcriptase polymerase chain reaction (RT-PCR), a method for amplifying RNA molecules into DNA. This method allows for the rapid production and analysis of large amounts of genetic material. The company is divided into several divisions, including ophthalmology, inflammatory diseases, oncology, and neurology. Regeneron also produces a wide range of biopharmaceutical products, including antibodies, interleukins, enzymes, and fusion proteins. One of Regeneron's most popular products is EYLEA (Aflibercept), a medication used to treat retinal diseases such as age-related macular degeneration. EYLEA has been on the market since 2011 and has proven to be highly effective. The medication is a blockbuster for Regeneron and accounts for a significant portion of its product revenue. Another important product from Regeneron is Dupixent (Dupilumab), a medication used to treat atopic dermatitis and severe asthma. The medication has been on the market since 2017 and has quickly established itself as a key treatment for asthma. Dupixent is produced in collaboration with Sanofi. Regeneron has also conducted promising research in the field of oncology. The company has developed a range of cancer therapies that are in the clinical phase of development. One example is the antibody Libtayo, which is used to treat squamous cell carcinomas. In its recent history, Regeneron has played a major role in the research and development of antibodies for the treatment of COVID-19. Regeneron was the first company to receive funding from the US government for the development of an antibody cocktail for the treatment of COVID-19. The medication, consisting of the antibodies Casirivimab and Imdevimab, was granted emergency use authorization by the US Food and Drug Administration in November 2020. Regeneron also has an extensive partnership with pharmaceutical company Sanofi. The two companies have jointly developed products such as Praluent (Alirocumab), a medication used to lower cholesterol levels, and Kevzara (Sarilumab), a medication used to treat rheumatoid arthritis. Overall, in recent years, Regeneron has built a strong position as a leading biotechnology company. The company has an impressive product pipeline and has developed a wide range of important medications. Regeneron continues to work on the development of new therapies and has the potential to play a significant role in the biotechnology industry in the coming years. Regeneron Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Regeneron Pharmaceuticals revenue by segment

In the annual report of the Regeneron Pharmaceuticals share (US75886F1075, 881535, REGN), it breaks down its revenues into 1 segments: 1. Medicines. The Regeneron Pharmaceuticals stock (WKN: 881535, ISIN: US75886F1075, Ticker Symbol: REGN) is a leading investment for investors interested in participating in the Health Care sector.

  • 100 % Medicines

Net Income Details

Understanding Regeneron Pharmaceuticals's Profit Margins

The profit margins of Regeneron Pharmaceuticals represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Regeneron Pharmaceuticals's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Regeneron Pharmaceuticals's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Regeneron Pharmaceuticals's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Regeneron Pharmaceuticals’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Regeneron Pharmaceuticals stock

How much profit has Regeneron Pharmaceuticals made this year?

Regeneron Pharmaceuticals has made 5.07 B USD this year.

How has the profit developed compared to last year?

The profit has increased by 28.13% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Regeneron Pharmaceuticals publish its earnings?

Regeneron Pharmaceuticals publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Regeneron Pharmaceuticals?

The profits of Regeneron Pharmaceuticals are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Regeneron Pharmaceuticals?

You can learn more about the earnings of Regeneron Pharmaceuticals by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Regeneron Pharmaceuticals pay?

Over the past 12 months, Regeneron Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Regeneron Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Regeneron Pharmaceuticals?

The current dividend yield of Regeneron Pharmaceuticals is .

When does Regeneron Pharmaceuticals pay dividends?

Regeneron Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Regeneron Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Regeneron Pharmaceuticals located?

Regeneron Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Regeneron Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Regeneron Pharmaceuticals from 10/23/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/23/2024.

When did Regeneron Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/23/2024.

What was the dividend of Regeneron Pharmaceuticals in the year 2023?

In the year 2023, Regeneron Pharmaceuticals distributed 0 USD as dividends.

In which currency does Regeneron Pharmaceuticals pay out the dividend?

The dividends of Regeneron Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Regeneron Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic, ING, Scalable Capital and Consorsbank

Andere Kennzahlen von Regeneron Pharmaceuticals

Our stock analysis for Regeneron Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Regeneron Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.